Enterome vs Poplar Therapeutics
Enterome vs Poplar Therapeutics, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Enterome is on 60/100 and Poplar Therapeutics on 51/100.
Where each one leads
Enterome
- our overall score: 60/100 against 51/100
- domain rating: 46/100 against 4/100
- headcount: 33 against 15
- funding raised: $124M against $50.0M
- LinkedIn following: 16,846 against 1,205
Poplar Therapeutics
- agent readiness: 40/100 against 21/100
At a glance
| Measure | Enterome | Poplar Therapeutics |
|---|---|---|
| What it is | Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases. | Developing a new class of anti-IgE therapy for multiple atopic conditions. |
| Category | Biotechnology, Drug Discovery, Oncology, Immunotherapy | Biotechnology, Pharmaceuticals, HealthTech, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Services |
| Founded | 2012 | 2021 |
| Headquarters | Paris, France | Boston, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Enterome | Poplar Therapeutics |
|---|---|---|
| Employees | 33 | 15 |
| Total funding | $124M | $50.0M |
| Latest round | Later Stage VC | Series A |
| LinkedIn followers | 16,846 | 1,205 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Enterome | Poplar Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 60/100 | 51/100 |
| Traction | 55/100 | 51/100 |
| Team | 70/100 | 30/100 |
| Search visibility | 34/100 | 25/100 |
| Quality | 68/100 | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 46/100 | 4/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Enterome | Poplar Therapeutics |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CDN | Not detected | Cloudflare |
| CMS | WordPress | WordPress |
| Frameworks | Bootstrap | Jquery |
| Analytics | Google Analytics 4, Segment | Google Analytics 4 |
Enterome vs Poplar Therapeutics: common questions
Which is better, Enterome or Poplar Therapeutics?
On our 0-100 score Enterome rates higher (60/100 against 51/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do Enterome and Poplar Therapeutics compare on the numbers?
Enterome leads on our overall score (60/100 against 51/100), domain rating (46/100 against 4/100), headcount (33 against 15), funding raised ($124M against $50.0M), LinkedIn following (16,846 against 1,205). Poplar Therapeutics leads on agent readiness (40/100 against 21/100).
Read the full Enterome review and pricing or the Poplar Therapeutics review and pricing. You can also browse other Enterome alternatives we track.